
Sandra E Fischer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1849291/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	9.4	676
2	Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clinical Cancer Research, 2018, 24, 1344-1354.	7.0	414
3	Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nature Genetics, 2020, 52, 231-240.	21.4	365
4	Handheld Computing in Medicine. Journal of the American Medical Informatics Association: JAMIA, 2003, 10, 139-149.	4.4	285
5	Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0151829.	2.5	284
6	Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. Journal of Hepatology, 2017, 67, 92-99.	3.7	226
7	Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Scientific Reports, 2018, 8, 1466.	3.3	196
8	GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 4901-4910.	7.0	191
9	Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell, 2021, 184, 5577-5592.e18.	28.9	182
10	Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Cancer Cell, 2019, 35, 267-282.e7.	16.8	151
11	Single ell, Singleâ€Nucleus, and Spatial RNA Sequencing of the Human Liver Identifies Cholangiocyte and Mesenchymal Heterogeneity. Hepatology Communications, 2022, 6, 821-840.	4.3	98
12	A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 1997-2010.	7.0	91
13	Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. Transplant International, 2010, 23, 299-306.	1.6	89
14	Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2021, 160, 2119-2132.e9.	1.3	83
15	Altered hepatic genes related to retinol metabolism and plasma retinol in patients with non-alcoholic fatty liver disease. PLoS ONE, 2018, 13, e0205747.	2.5	71
16	Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning?. European Radiology, 2021, 31, 244-255.	4.5	67
17	Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis. PLoS ONE, 2017, 12, e0189223.	2.5	61
18	Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. Cancer Research, 2020, 80, 2804-2817.	0.9	58

SANDRA E FISCHER

#	Article	IF	CITATIONS
19	Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. PLoS Computational Biology, 2019, 15, e1006596.	3.2	51
20	Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Gut, 2021, 70, 1894-1903.	12.1	49
21	MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma. Cancer Imaging, 2018, 18, 8.	2.8	44
22	Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet. Obesity Surgery, 2018, 28, 1109-1116.	2.1	40
23	Prediction of the histopathologic findings of intrahepatic cholangiocarcinoma: qualitative and quantitative assessment of diffusion-weighted imaging. European Radiology, 2018, 28, 2047-2057.	4.5	34
24	Can negligible hepatic steatosis determined by magnetic resonance imaging–proton density fat fraction obviate the need for liver biopsy in potential liver donors?. Liver Transplantation, 2018, 24, 470-477.	2.4	31
25	Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation. Liver Transplantation, 2016, 22, 1295-1300.	2.4	29
26	Primary perivascular epithelioid cell tumors of the liver: CT/MRI findings and clinical outcomes. Abdominal Radiology, 2017, 42, 1705-1712.	2.1	27
27	Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. International Journal of Experimental Pathology, 2014, 95, 209-215.	1.3	26
28	Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease. Nutrition, 2019, 62, 100-107.	2.4	26
29	Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. Abdominal Radiology, 2019, 44, 1795-1807.	2.1	25
30	In nonalcoholic fatty liver disease, Roux-en-Y gastric bypass improves liver histology while persistent disease is associated with lower improvements in waist circumference and glycemic control. Surgery for Obesity and Related Diseases, 2018, 14, 1233-1239.	1.2	24
31	A clinicalâ€radiomic model for improved prognostication of surgical candidates with colorectal liver metastases. Journal of Surgical Oncology, 2020, 121, 357-364.	1.7	24
32	The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis. European Radiology, 2019, 29, 1039-1047.	4.5	22
33	A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 5462-5476.	7.0	20
34	Prospective comparison of gadoxetic acid-enhanced liver MRI and contrast-enhanced CT with histopathological correlation for preoperative detection of colorectal liver metastases following chemotherapy and potential impact on surgical plan. Hpb, 2017, 19, 992-1000.	0.3	18
35	Markers of activated inflammatory cells are associated with disease severity and intestinal microbiota in2adults with nonâ€alcoholic fatty liver disease. International Journal of Molecular Medicine, 2018, 42, 2229-2237.	4.0	18
36	Diffusion-weighted and hepatobiliary phase gadoxetic acid-enhanced quantitative MR imaging for identification of complete pathologic response in colorectal liver metastases after preoperative chemotherapy. Abdominal Radiology, 2016, 41, 231-238.	2.1	17

SANDRA E FISCHER

#	Article	IF	CITATIONS
37	Surgical procedure logging with use of a hand-held computer. Canadian Journal of Surgery, 2002, 45, 345-50.	1.2	17
38	The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Scientific Reports, 2021, 11, 14951.	3.3	15
39	Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease in Obese Patients Undergoing Bariatric Surgery. Obesity Surgery, 2020, 30, 2572-2578.	2.1	14
40	Molecular characterisation of pancreatic ductal adenocarcinoma with <i>NTRK</i> fusions and review of the literature. Journal of Clinical Pathology, 2023, 76, 158-165.	2.0	11
41	Integrative molecular profiling and response to chemotherapy on the COMPASS trial Journal of Clinical Oncology, 2019, 37, 188-188.	1.6	9
42	Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan. Clinical Proteomics, 2021, 18, 27.	2.1	9
43	Utility of shearâ€wave elastography to differentiate low from advanced degrees of liver fibrosis in patients with hepatitis C virus infection of native and transplant livers. Journal of Clinical Ultrasound, 2018, 46, 311-318.	0.8	7
44	Metastatic Hepatocellular Carcinoma in a Patient with Crohn's Disease Treated with Azathioprine and Infliximab: A Case Report and Literature Review. Case Reports in Gastrointestinal Medicine, 2014, 2014, 1-4.	0.3	6
45	Single-Center North American Experience of Liver Transplantation in Autoimmune Hepatitis: Infrequent Indication but Good Outcomes for Patients. Journal of the Canadian Association of Gastroenterology, 2021, 4, 137-144.	0.3	6
46	Comparison of bioelectrical impedance analysis, mass index, and waist circumference in assessing risk for non-alcoholic steatohepatitis. Nutrition, 2022, 93, 111491.	2.4	6
47	Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2022, 12, 860767.	2.8	6
48	Effect of portal vein embolization on treatment plan prior to major hepatectomy for hepatocellular carcinoma. Hpb, 2019, 21, 1072-1078.	0.3	5
49	Radiological tumor response and histopathological correlation of hepatocellular carcinoma treated with stereotactic body radiation therapy as a bridge to liver transplantation. Abdominal Radiology, 2021, 46, 1572-1585.	2.1	5
50	Recurrent Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Directions. Seminars in Liver Disease, 2021, 41, 409-420.	3.6	4
51	Homologous recombination deficiency (HRD) scoring in pancreatic ductal adenocarcinoma (PDAC) and response to chemotherapy Journal of Clinical Oncology, 2020, 38, 741-741.	1.6	4
52	GATA6 Expression as a predictor of response to perioperative chemotherapy in resectable pancreatic adenocarcinoma: A multicenter Canadian phase II study (NeoPancONE) Journal of Clinical Oncology, 2022, 40, TPS638-TPS638.	1.6	4
53	Is Biannual Surveillance for Pancreatic Cancer Sufficient in Individuals With Genetic Syndromes or Familial Pancreatic Cancer?. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 663-673.e12.	4.9	3
54	Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC) Journal of Clinical Oncology, 2021, 39, 4142-4142.	1.6	2

SANDRA E FISCHER

#	Article	IF	CITATIONS
55	hENT1 gene expression as a predictor of response to gemcitabine and nab-paclitaxel in advanced pancreatic cancer Journal of Clinical Oncology, 2021, 39, 4011-4011.	1.6	2
56	Outcomes and Immunogenicity of pancreatic cancer stratified by the HRDetect score Journal of Clinical Oncology, 2020, 38, 4630-4630.	1.6	2
57	Reduced Complications after Arterial Reconnection in a Rat Model of Orthotopic Liver Transplantation. Journal of Visualized Experiments, 2020, , .	0.3	2
58	Liver resection for multifocal hepatocellular carcinoma Journal of Clinical Oncology, 2012, 30, 355-355.	1.6	2
59	Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Clinical Cancer Research, 2022, 28, 2715-2715.	7.0	2
60	Molecular characterization of long-term and short-term survivors of advanced pancreatic ductal adenocarcinoma Journal of Clinical Oncology, 2022, 40, 4024-4024.	1.6	2
61	Severe lactic acidosis due to excessive consumption of Cellucor C4 exercise supplement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, , 1-4.	0.5	1
62	Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy. Journal of Clinical Pathology, 2019, 72, 112-119.	2.0	1
63	Genomic characterization of ATM alterations in advanced pancreatic ductal adenocarcinoma (PDAC) Journal of Clinical Oncology, 2021, 39, 396-396.	1.6	1
64	Genomics-driven precision medicine for advanced pancreatic ductal carcinoma (PDAC): Early results from the COMPASS trial (NCT02750657) Journal of Clinical Oncology, 2018, 36, 211-211.	1.6	1
65	Prognostic ability of the Gustave Roussy Immune Score for patients with advanced pancreatic adenocarcinoma Journal of Clinical Oncology, 2022, 40, 469-469.	1.6	1
66	Comparison of systematic inflammatory prognostic scores in patients with advanced pancreatic adenocarcinoma Journal of Clinical Oncology, 2022, 40, 4149-4149.	1.6	1
67	Prospective genomic/transcriptomic profiling of advanced pancreatic ductal adenocarcinoma (PDAC) for personalized therapy: Feasibility and preliminary results from the COMPASS study (NCT02750657) Journal of Clinical Oncology, 2017, 35, e15776-e15776.	1.6	0
68	Clinical and molecular profiling of locally advanced compared with metastatic pancreatic adenocarcinoma Journal of Clinical Oncology, 2020, 38, 747-747.	1.6	0